+86-27-65522453 sales@sun-shinechem.com

Naquotinib

Catalog No.: 16071107
Cas No.: 448232-80-1
Purity : 98% by HPLC 
16071107 - Naquotinib | CAS 448232-80-1

Catalog number : 16071107

CAS number : 448232-80-1

Molecular Formula : C30H42N8O3 

Molecular Weight : 562.719 

Iupac Chemical Name : (R)-5-((1-acryloylpyrrolidin-3-yl)oxy)-6-ethyl-3-((4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrazine-2-carboxamide 

Smile : C(C=C)(=O)N1C[C@@H](CC1)OC=1N=C(C(=NC1CC)C(=O)N)NC1=CC=C(C=C1)N1CCC(CC1)N1CCN(CC1)C

InChiKey : QKDCLUARMDUUKN-XMMPIXPASA-N

PackagingPriceAvailabilityPurityEstimated Shipping Time
BulkEnquiryEnquiry
Request Bulk Quote Download MSDSTel:+86-27-65522453 | Email:sales@sun-shinechem.com
SynonymsASP8273; ASP-8273; 
Molecular FormulaC30H42N8O3 
Molecular Weight562.719 
AppearanceSolid powder 
Purity98% by HPLC 
SolubilitySoluble in DMSO 
Storage-20 ºC for 3 years 
Shipping ConditionShipped under ambient temperature 
SmileC(C=C)(=O)N1C[C@@H](CC1)OC=1N=C(C(=NC1CC)C(=O)N)NC1=CC=C(C=C1)N1CCC(CC1)N1CCN(CC1)C
InChiKeyQKDCLUARMDUUKN-XMMPIXPASA-N
InChiInChI=1S/C30H42N8O3/c1-4-25-30(41-24-12-15-38(20-24)26(39)5-2)34-29(27(33-25)28(31)40)32-21-6-8-22(9-7-21)36-13-10-23(11-14-36)37-18-16-35(3)17-19-37/h5-9,23-24H,2,4,10-20H2,1,3H3,(H2,31,40)(H,32,34)/t24-/m1/s1
Coming soon.
Naquotinib, also known as ASP8273, is an orally available, irreversible, third-generation, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, ASP8273 covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. ASP8273 preferentially inhibits mutated forms of EGFR including T790M, a secondarily acquired resistance mutation, and may have therapeutic benefits in tumors with T790M-mediated resistance when compared to other EGFR tyrosine kinase inhibitors.  

448232-80-1 - Request Bulk Quote

×
448232-80-1 - Request Bulk Quote
Change